Randomised controlled trial of Vinehealth digital health cancer solution

ABSTRACT: Background and study aims Chemotherapy is a common treatment for people with cancer. It can be associated with a number of side effects and symptoms, which if not adequately managed can have a negative impact on the lives of people living with cancer. Chemotherapy is often delivered on an outpatient basis and most people have to manage the side effects of their treatment at home, with limited input from health professionals. Therefore, it is important to look at ways of supporting people receiving chemotherapy to manage their symptoms and therefore improve their quality of life during periods when they are at home. Researchers are conducting a large trial in 240 people to evaluate the impact of the use of the Vinehealth® app to help manage symptoms and side effects and hopefully improve the quality of life of people with breast, bowel or lung cancer. This is for patients who have just had surgery for their cancer and are about to start chemotherapy as part of their treatment for their cancer. Participation will last for 24 weeks. The main aim of the trial is to see if using the Vinehealth® app in addition to usual care is better or worse than usual care on its own in the reporting and management of chemotherapy-related symptoms to help improve quality of life in the 24 weeks from the start of chemotherapy treatment. Who can participate? Patients aged 18 years or over who have had surgery for their cancer and are about to begin at least 12 weeks of chemotherapy treatment for their cancer What does the study involve? Once eligibility is confirmed patients will be randomly allocated into two groups using an online randomisation platform. One group will use the Vinehealth® app to log symptoms, complete questionnaires and find information for self-management, whilst the other group will complete questionnaires on paper and receive care that is usually provided at their hospital. Patients will participate in the trial for 24 weeks during their chemotherapy treatment period. The groups that patients will be allocated into will be selected by a computer, which has no information about the individual, so people will be selected by chance. Patients in both groups will have their quality of life compared to see if one is better than the other. Other information, such as symptoms, other outcomes, supportive care needs, work limitations, confidence in their ability to complete tasks, and anxiety, will also be compared across both groups.

DISEASE(S): Colorectal,Breast And Lung Cancer Patients Commencing Adjuvant Systemic Treatment

PROVIDER: 2753984 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR